950220 — Neoimmunetech Income Statement
0.000.00%
Last trade - 00:00- KR₩115bn
- KR₩91bn
- $0.12m
Annual income statement for Neoimmunetech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0.125 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 26.5 | 45.4 | 45 | 42.6 | 29.8 |
| Operating Profit | -26.5 | -45.4 | -45 | -42.6 | -29.7 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -25.8 | -45.8 | -46.7 | -40.8 | -30 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -25.8 | -45.9 | -46.8 | -40.9 | -30 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -25.8 | -45.9 | -46.8 | -40.9 | -30 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -25.8 | -45.9 | -46.8 | -40.9 | -30 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.56 | -2.4 | -2.37 | -2.07 | -1.5 |
| Dividends per Share |